Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) has provided an update.
CStone Pharmaceuticals has announced the appointment of Ms. Fang Xie as an independent non-executive director and chairperson of the audit committee, effective November 1, 2025. Ms. Xie brings over 30 years of experience in operational finance and management consulting, having served in various leadership roles in prominent companies. Her appointment follows the resignation of Ms. Yip Betty Ho, who stepped down to focus on personal commitments. The changes in the board are expected to strengthen CStone’s governance and strategic direction, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing and commercializing innovative immuno-oncology and precision medicine therapies to address unmet medical needs in cancer treatment.
Average Trading Volume: 22,471,424
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.1B
Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.